Zura Bio

In 2024, pharma saw breakthroughs like Amtagvi for solid tumors and Cobenfy for schizophrenia. Challenges include the Inflation Reduction Act's price negotiations and R&D financial pressures. Innovations expected in 2025 include SERDs for breast cancer, bispecific antibodies in immuno-oncology, and the first tri-specific antibody approval. Clinical trials will evolve with external control arms and adaptive designs, while policy shifts may impact rare disease R&D and obesity care coverage.

Zura Bio initiated the Phase II TibuSURE trial to assess tibulizumab, a tetravalent bispecific antibody, for systemic sclerosis (SSc). The trial involves 80 subjects with early diffuse cutaneous SSc, with a 24-week efficacy period and a 28-week open-label extension. Modified Rodnan Skin Score (mRSS) is the primary endpoint, focusing on lung disease, physical function, and the revised Combined Response Index in SSc. Tibulizumab combines Taltz and tabalumab to neutralise IL-17A and BAFF, with potential for Phase II hidradenitis suppurativa study next year.

H.C. Wainwright maintains Buy rating and $15.00 target for Zura Bio Ltd (NASDAQ:ZURA) following TibuSURE Phase 2 study launch for tibulizumab in systemic sclerosis. Analysts remain bullish with targets ranging from $5 to $26. Zura Bio's strong liquidity and financial flexibility support its clinical development programs. The TibuSURE study aims to assess tibulizumab's safety, tolerability, and efficacy in early diffuse cutaneous systemic sclerosis. Positive results could significantly impact Zura Bio's stock performance and market valuation.

Zura Bio launches TibuSURE, a Phase 2 study evaluating tibulizumab for systemic sclerosis, targeting anti-BAFF and IL-17 pathways.

Zura Bio launches TibuSURE, a global Phase 2 study evaluating tibulizumab for systemic sclerosis in adults, targeting both anti-BAFF and IL-17 pathways for deeper efficacy.

Nodenza Venture Partners launched to support early-stage and pre-commercial biotech & medtech companies, focusing on disruptive technologies and therapies with potential for exceptional patient benefits. The team, led by Ross Morton, combines expertise in drug development and commercialization to invest in 3-4 opportunities in the first year.